Although I do have a small position, Im not buying in big until the "other shoe" drops
It's not that I don't think this company has a future, it does. In fact, it's prospects are just as good or better than most small cap drug development firms. The problem is, CLSN does not have the cash to complete the clinical trials they already have underway - and that's WITH the 5 million from the HISUN deal. My suspicion is that any decent cash raise could bring the stock in half. Legitimate contrary opinions welcome. Im not a basher so please don't treat me as such. Im simply not a huge gambler.
The pumping is egregious here. The stock will not see 8 bucks a share for at least a year or more. The drug delivery system does not work.... The jump from phase 1 to phase 3 studies was too large and too many variables were unnacounted for. More basic R and D must be done and the delivery system re engineered. Phase 2 should have been done imo with a small 20 or 30 patient population.